Aclaris Therapeutics ACRS Royalty income
Royalty income at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyIncomeNonoperating.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's royalty income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's royalty income?
- Aclaris Therapeutics (ACRS) reported royalty income of $854K in Q1 2026.
- How has Aclaris Therapeutics's royalty income changed year-over-year?
- Aclaris Therapeutics's royalty income increased by 2.5% year-over-year, from $833K to $854K.
- What does royalty income mean?
- Represents revenue generated from licensing the company's intellectual property or technology to third parties in exchange for a percentage of their sales. This income stream is typically non-operational and reflects the monetization of the company's research efforts without requiring direct commercialization efforts. It provides a valuable, often high-margin, supplement to the company's primary therapeutic and research service revenue.